

Special Issue

Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma

Message from the Guest Editors

Immune checkpoints are key regulators of the immune system and protect the host from autoimmune responses. Immune checkpoints can also be expressed on the surface of tumor cells and promote an immunosuppressive microenvironment that supports tumor growth. The blockade of immune checkpoints restores the activation of the immune system towards tumor cells. Multiple ICIs have been approved by the FDA for RCC therapies, including monoclonal antibodies that target the cytotoxic T-lymphocyte-associated protein-4 (CTLA-A4) or the programmed death-1 (PD-1). These antibodies are efficient and safe as monotherapy, in combination with other ICIs or with anti-angiogenic therapeutic compounds (the therapeutic references for 15 years). Thus, therapies based on ICIs are now recommended as the first-line therapy in clear-cell cancers with the observation of long-lasting disease control.

Guest Editors

Dr. Thierry Massfelder

Dr. Philippe Barthélémy

Dr. Valerian Dormoy

Dr. Mamatha Garige

Deadline for manuscript submissions

closed (30 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/105698

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)